Romosozumab in Postmenopausal Women with Low Bone Mineral Density
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. METHODS: In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85 years of age, who had low bone mineral density (a T score of -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the three sites). Participants were randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 months (140 mg or 210 mg), subcutaneous placebo, or an open-label active comparator--oral alendronate (70 mg weekly) or subcutaneous teriparatide (20 μg daily). The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Secondary end points included percentage changes in bone mineral density at other sites and in markers of bone turnover. RESULTS: All dose levels of romosozumab were associated with significant increases in bone mineral density at the lumbar spine, including an increase of 11.3% with the 210-mg monthly dose, as compared with a decrease of 0.1% with placebo and increases of 4.1% with alendronate and 7.1% with teriparatide. Romosozumab was also associated with large increases in bone mineral density at the total hip and femoral neck, as well as transitory increases in bone-formation markers and sustained decreases in a bone-resorption marker. Except for mild, generally nonrecurring injection-site reactions with romosozumab, adverse events were similar among groups. CONCLUSIONS: In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. (Funded by Amgen and UCB Pharma; ClinicalTrials.gov number, NCT00896532.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the simultaneous, acute increase in P1NP and reduction in CTx that we observed in the T3 group is qualitatively identical (but smaller in magnitude) to the effects of sclerostin inhibition on bone markers in humans22, and arguably pathognomonic of the consequences of sclerostin inhibition on bone.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
In the citing paper
“the time course of changes in bone formation we observed over 20 weeks of intermittent D + Q treatment in the T3 group is virtually identical (albeit smaller in magnitude) to that observed following treatment with the FDA-approved sclerostin inhibitor, romosozumab, where serum P1NP increased rapidly over the first 1–4 weeks following dosing and then returned to baseline by 24 weeks22.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 936
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G., Stouch, B., Fang, L., & Posvar, E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Baron, R., & Rawadi, G. (2007) · Endocrinology · doi:10.1210/en.2007-0270 · Cited by 584
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442
Cited by
Items 201–300 of 1,000
Sclerostin in chronic kidney disease–mineral bone disorder think first before you block it!
Brandenburg, V. M., Verhulst, A., Babler, A., D'Haese, P. C., Evenepoel, P., & Kaesler, N. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy129 · Cited by 75
Rolvien, T., Milovanovic, P. D., Schmidt, F. N., Kroge, S. V., Wölfel, E. M., Krause, M., Wulff, B., Püschel, K., Ritchie, R. O., Amling, M., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3970 · Cited by 83
Effects of Age and Estrogen on Skeletal Gene Expression in Humans as Assessed by RNA Sequencing
Farr, J. N., Roforth, M. M., Fujita, K., Nicks, K. M., Cunningham, J. M., Atkinson, E. J., Therneau, T. M., McCready, L. K., Peterson, J. M., Drake, M. T., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138347 · Cited by 75
Nioi, P., Taylor, S., Hu, R., Pacheco, E., He, Y. D., Hamadeh, H., Paszty, C., Pyrah, I., Ominsky, M. S., & Boyce, R. W. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2482 · Cited by 74
Bone biology, signaling pathways, and therapeutic targets for osteoporosis
Iñiguez‐Ariza, N. M., & Clarke, B. L. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.07.003 · Cited by 94
Sclerostin Inhibition in the Management of Osteoporosis
Appelman‐Dijkstra, N. M., & Papapoulos, S. E. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0126-6 · Cited by 80
Effects of Anorexia Nervosa on Bone Metabolism
Fazeli, P. K., & Klibanski, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00063 · Cited by 87
Ebina, K., Hirao, M., Tsuboi, H., Nagayama, Y., Kashii, M., Kaneshiro, S., Miyama, A., Nakaya, H., Kunugiza, Y., Okamura, G., et al. (2020) · Bone · doi:10.1016/j.bone.2020.115574 · Cited by 71
Artsi, H., Cohen-Kfir, E., Gurt, I., Shahar, R., Bajayo, A., Kalish, N., Bellido, T. M., Gabet, Y., & Dresner-Pollak, R. (2014) · Endocrinology · doi:10.1210/en.2014-1334 · Cited by 73
The multi-faceted nature of age-associated osteoporosis
Smit, A. E., Meijer, O. C., & Winter, E. M. (2024) · Bone Reports · doi:10.1016/j.bonr.2024.101750 · Cited by 94
Bone Biology and Anabolic Therapies for Bone: Current Status and Future Prospects
Martin, T. J. (2014) · Journal of Bone Metabolism · doi:10.11005/jbm.2014.21.1.8 · Cited by 81
Kelly, N. H., Schimenti, J. C., Ross, F. P., & van der Meulen, M. C. H. (2016) · Bone · doi:10.1016/j.bone.2016.02.007 · Cited by 89
Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway
Appelman‐Dijkstra, N. M., & Papapoulos, S. E. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0087-0 · Cited by 76
Li, X., Niu, Q.-T., Warmington, K. S., Asuncion, F. J., Dwyer, D., Grisanti, M., Han, C.-Y., Stolina, M., Eschenberg, M. J., Kostenuik, P. J., et al. (2014) · Endocrinology · doi:10.1210/en.2013-1905 · Cited by 70
Sinder, B. P., WHITE, L. E., Salemi, J. L., Ominsky, M. S., Caird, M. S., Marini, J. C., & Kozloff, K. M. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2737-y · Cited by 71
Romosozumab in Postmenopausal Women with Osteopenia
Evenepoel, P., D'Haese, P., & Brandenburg, V. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1402396 · Cited by 71
Novel therapies for osteoporosis
Makras, P., Delaroudis, S., & Anastasilakis, A. D. (2015) · Metabolism · doi:10.1016/j.metabol.2015.07.011 · Cited by 80
Biological agents in management of osteoporosis
Tella, S. H., & Gallagher, J. C. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1735-5 · Cited by 77
Qin, W., Li, X., Peng, Y., Harlow, L. M., Ren, Y., Wu, Y., Li, J., Qin, Y., Sun, J., Zheng, S., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2549 · Cited by 75
Anti-sclerostin antibodies: Utility in treatment of osteoporosis
Clarke, B. L. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.04.016 · Cited by 70
Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential
McClung, M. R. (2017) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x17726744 · Cited by 69
Self-citationManagement of Postmenopausal Osteoporosis
Andreopoulou, P., & Bockman, R. S. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-070313-022841 · Cited by 69
Jia, H., Ma, X., Wei, Y., Tong, W., Tower, R. J., Chandra, A., Wang, L., Sun, Z., Yang, Z., Badar, F., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40351 · Cited by 72
Sclerostin Protects Against Vascular Calcification Development in Mice
Maré, A. D., Opdebeeck, B., Neven, E., D’Haese, P. C., & Verhulst, A. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4503 · Cited by 68
Evenepoel, P., Goffin, E. J., Meijers, B. K. I., Kanaan, N., Bammens, B., Coche, E., Claes, K. J., & Jadoul, M. Y. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3056 · Cited by 70
Hamann, C., Picke, A.-K., Campbell, G. M., Balyura, M., Rauner, M., Bernhardt, R., Huber, G., Morlock, M. M., Günther, K.-P., Bornstein, S. R., et al. (2014) · Endocrinology · doi:10.1210/en.2013-1960 · Cited by 68
Chronic kidney disease and the skeleton
Miller, P. D. (2014) · Bone Research · doi:10.1038/boneres.2014.44 · Cited by 76
Muscle and bone effects of androgen deprivation therapy: current and emerging therapies
Cheung, A. S., Zajac, J. D., & Grossmann, M. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0172 · Cited by 71
Mouse Models in Bone Fracture Healing Research
Haffner‐Luntzer, M., Kovtun, A., Rapp, A. E., & Ignatius, A. A. (2016) · Current Molecular Biology Reports · doi:10.1007/s40610-016-0037-3 · Cited by 77
Sclerostin Antibody Treatment Enhances Rotator Cuff Tendon-to-Bone Healing in an Animal Model
Shah, S. A., Kormpakis, I., Havlioglu, N., Ominsky, M. S., Galatz, L. M., & Thomopoulos, S. (2017) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.16.01019 · Cited by 70
Sølling, A. S. K., Harsløf, T., & Langdahl, B. (2018) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x18775936 · Cited by 68
Self-citationGlucocorticoid-induced autophagy and apoptosis in bone
Wang, T., Liu, X., & He, C. (2020) · APOPTOSIS · doi:10.1007/s10495-020-01599-0 · Cited by 67
Wei, H., Xu, Y., Wang, Y., Xu, L., Mo, C., Li, L., Shen, B., Sun, Y., Cheng, P., Yang, L., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108252 · Cited by 72
Anabolic actions of Notch on mature bone
Liu, P., Ping, Y., Ma, M., Zhang, D., Liu, C. S., Zaidi, S., Gao, S., Ji, Y., Lou, F., Yu, F., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603399113 · Cited by 71
Use of bone turnover markers in the management of osteoporosis
Jain, S., & Camacho, P. M. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000446 · Cited by 67
Sclerostin Inhibition Prevents Spinal Cord Injury-Induced Cancellous Bone Loss
Beggs, L. A., Ye, F., Ghosh, P., Beck, D. T., Conover, C. F., Balaez, A., Miller, J. R., Phillips, E. G., Zheng, N. N., Williams, A. A., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2396 · Cited by 69
Current approaches to osteoporosis treatment
Lim, S. Y., & Bolster, M. B. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000169 · Cited by 71
Holdsworth, G., Greenslade, K. J., Jose, J., Stencel, Z., Kirby, H., Moore, A., Ke, H. Z., & Robinson, M. K. (2017) · Bone · doi:10.1016/j.bone.2017.11.003 · Cited by 69
Medical complications of anorexia nervosa and their treatments: an update on some critical aspects
Brown, C., & Mehler, P. S. (2015) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-015-0202-3 · Cited by 83
Biology and treatment of myeloma related bone disease
Terpos, E., Christoulas, D., & Gavriatopoulou, M. (2017) · Metabolism · doi:10.1016/j.metabol.2017.11.012 · Cited by 72
Ferrari, S., Lippuner, K., Lamy, O., & Meier, C. (2020) · Swiss Medical Weekly · doi:10.4414/smw.2020.20352 · Cited by 69
Cavalier, E., Bergmann, P., Bruyère, O., Delanaye, P., Durnez, A., Devogelaer, J.-P., Ferrari, S. L., Gielen, E., Goemaere, S., Kaufman, J.-M., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3561-3 · Cited by 63
Self-citationPietrzyk, B., Smertka, M., & Chudek, J. T. (2017) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/68739 · Cited by 68
Role of nutritional vitamin D in osteoporosis treatment
Hou, Y., Wu, C., Liao, M.-T., Shyu, J., Hung, C., Yen, T., Lu, C., & Lu, K. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.05.035 · Cited by 70
Osteoporosis: a clinical and pharmacological update
Vidal, M., Thibodaux, R. J., Neira, L. F. V., & Messina, O. D. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4370-1 · Cited by 67
Brandenburg, V. M., D’Haese, P. C., Deck, A., Mekahli, D., Meijers, B. K. I., Neven, E., & Evenepoel, P. (2015) · Pediatric Nephrology · doi:10.1007/s00467-015-3069-7 · Cited by 67
Milk extracellular vesicles accelerate osteoblastogenesis but impair bone matrix formation
Oliveira, M. C., Arntz, O. J., Davidson, E. N. B., van Lent, P. L. E. M., Koenders, M. I., van der Kraan, P. M., van den Berg, W. B., Ferreira, A. V. M., & van de Loo, F. A. J. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.11.017 · Cited by 64
Séror, R., Boudaoud, S., Pavy, S., Nocturne, G., Schaeverbeke, T., Saraux, A., Chanson, P., Gottenberg, J., Devauchelle‐Pensec, V., Tobón, G. J., et al. (2016) · Scientific Reports · doi:10.1038/srep18421 · Cited by 67
Mechanisms of bone destruction in multiple myeloma
Terpos, E., Christoulas, D., Gavriatopoulou, M., & Dimopoulos, M. A. (2017) · European Journal of Cancer Care · doi:10.1111/ecc.12761 · Cited by 70
Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges
MacNabb, C., Patton, D., & Hayes, J. S. (2016) · Journal of Osteoporosis · doi:10.1155/2016/6217286 · Cited by 67
Sato, M., Inaba, M., Yamada, S., Emoto, M., Ohno, Y., & Tsujimoto, Y. (2021) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-021-01253-y · Cited by 61
Chandra, A., Lin, T., Zhu, J., Tong, W., Huo, Y., Jia, H., Zhang, Y., Liu, X. S., Cengel, K. A., Xia, B., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.608158 · Cited by 67
Clinical and Biological Determinants of Sclerostin Plasma Concentration in Hemodialysis Patients
Delanaye, P., Krzesinski, J.-M., Warling, X., Moonen, M., Smelten, N. S., Médart, L., Bruyère, O., Reginster, J., Pottel, H., & Cavalier, E. (2014) · Nephron Clinical Practice · doi:10.1159/000366449 · Cited by 65
Self-citationBone health in type 1 diabetes: focus on evaluation and treatment in clinical practice
Zhukouskaya, V. V., Eller-Vainicher, C., Shepelkevich, A. P., Дыдышко, Ю. В., Cairoli, E., & Chiodini, I. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0284-9 · Cited by 64
Sclerostin Antibody Treatment Improves Implant Fixation in a Model of Severe Osteoporosis
Virdi, A. S., Irish, J., Sena, K., Liu, M., Ke, H. Z., McNulty, M. A., & Sumner, D. R. (2015) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.n.00654 · Cited by 60
When, How, and Why a Bone Biopsy Should Be Performed in Patients With Chronic Kidney Disease
Ureña, P., Bover, J., Mazzaferro, S., de Vernejoul, M. C., & Cohen-Solal, M. E. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.09.004 · Cited by 64
Kim, R. Y., Yang, H. J., Song, Y. M., Kim, I. S., & Hwang, S. J. (2015) · Tissue Engineering Part A · doi:10.1089/ten.tea.2014.0585 · Cited by 61
Cosman, F., Lewiecki, E. M., Ebeling, P. R., Hesse, E., Napoli, N., Matsumoto, T., Crittenden, D. B., Rojeski, M., Yang, W., Libanati, C. R., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3996 · Cited by 62
Self-citationChen, H., Xu, X., Liu, M., Zhang, W., Ke, H.-Z., Qin, A., Tang, T., & Lu, E. (2015) · Bone · doi:10.1016/j.bone.2015.04.002 · Cited by 62
Novel advances in the treatment of osteoporosis
Chan, C. K. Y., Mason, A., Cooper, C. C., & Dennison, E. M. (2016) · British Medical Bulletin · doi:10.1093/bmb/ldw033 · Cited by 61
Pharmacological and biological therapeutic strategies for osteogenesis imperfecta
Marom, R., Lee, Y., Grafe, I., & Lee, B. (2016) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31532 · Cited by 72
In silico experiments of bone remodeling explore metabolic diseases and their drug treatment
Kameo, Y., Miya, Y., Hayashi, M., Nakashima, T., & Adachi, T. (2020) · Science Advances · doi:10.1126/sciadv.aax0938 · Cited by 58
Bone-derived factors mediate crosstalk between skeletal and extra-skeletal organs
He, T., Qin, L., Chen, S., Huo, S., Li, J., Zhang, F., Yi, W., Mei, Y., & Xiao, G. (2025) · Bone Research · doi:10.1038/s41413-025-00424-1 · Cited by 58
van der Burgh, A. C., de Keyser, C. E., Zillikens, M. C., & Stricker, B. H. C. (2021) · Drugs · doi:10.1007/s40265-021-01625-8 · Cited by 64
Dimai, H. P., & Fahrleitner‐Pammer, A. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101780 · Cited by 63
Osteoporosis and Multiple Sclerosis: Risk Factors, Pathophysiology, and Therapeutic Interventions
Gupta, S., Ahsan, I., Mahfooz, N., Abdelhamid, N., Ramanathan, M. K., & Weinstock‐Guttman, B. (2014) · CNS Drugs · doi:10.1007/s40263-014-0173-3 · Cited by 62
Tan, S. H., Senarath-Yapa, K., Chung, M. T., Longaker, M. T., Wu, J. Y., & Nusse, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420463111 · Cited by 60
Liu, Y., Cao, Y., Zhang, S., Zhang, W., Zhang, B., Tang, Q., Li, Z., & Wu, J. (2018) · Climacteric · doi:10.1080/13697137.2018.1433655 · Cited by 57
RETIRED: Osteoporosis in Menopause
Khan, A. A., Fortier, M. P., Fortier, M. P., Reid, R. L., Abramson, B. L., Blake, J. M., Desindes, S., Dodin, S., Graves, L. E., Guthrie, B., et al. (2014) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(15)30489-8 · Cited by 68
RetractedLRP receptor family member associated bone disease
Lara-Castillo, N., & Johnson, M. L. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-015-9315-2 · Cited by 56
The Role of PINP in Diagnosis and Management of Metabolic Bone Disease
Gillett, M. J., Vasikaran, S. D., & Inderjeeth, C. A. (2021) · Clinical Biochemist Reviews · doi:10.33176/aacb-20-0001 · Cited by 58
The Bone Morphogenetic Proteins and Their Antagonists
Mulloy, B., & Rider, C. C. (2015) · Vitamins and hormones · doi:10.1016/bs.vh.2015.06.004 · Cited by 67
Miyauchi, A., Dinavahi, R. V., Crittenden, D. B., Yang, W., Maddox, J., Hamaya, E., Nakamura, Y., Libanati, C. R., Grauer, A., & Shimauchi, J. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0608-z · Cited by 60
Self-citationRomosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture
Bhandari, M., Schemitsch, E. H., Karachalios, T. S., Sancheti, P. K., Poolman, R. W., Caminis, J. N., Daizadeh, N. S., Dent-Acosta, R. E., Egbuna, O. I., Chines, A. A., et al. (2020) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.19.01008 · Cited by 56
Komm, B. S., Morgenstern, D., Yamamoto, L. A., & Jenkins, S. N. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1099432 · Cited by 62
Sclerostin Blood Levels Before and After Kidney Transplantation
Bonani, M., Rodríguez, D., Fehr, T. H., Mohebbi, N., Brockmann, J. G., Blum, M., Graf, N., Frey, D., & Wuthrich, R. P. (2014) · Kidney & Blood Pressure Research · doi:10.1159/000355781 · Cited by 57
Liu, M., Kurimoto, P., Zhang, J., Niu, Q., Stolina, M., Dechow, P. C., Feng, J. Q., Hesterman, J. Y., Silva, M. D., Ominsky, M. S., et al. (2018) · Journal of Dental Research · doi:10.1177/0022034518766874 · Cited by 60
Novel insights into the complex architecture of osteoporosis molecular genetics
Saad, F. A. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14231 · Cited by 58
Kaveh, S., Hosseinifard, H., Ghadimi, N., Vojdanian, M., & Aryankhesal, A. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-04948-1 · Cited by 56
Bonnet, C., Brahmbhatt, A., Deng, S. X., & Zheng, J. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00063b · Cited by 58
Eriksen, E. F., Chapurlat, R. D., Boyce, R. W., Shi, Y., Brown, J. P., Horlait, S., Betah, D., Libanati, C. R., & Chavassieux, P. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4457 · Cited by 59
Self-citationInhaled Corticosteroids and Bone Health
Chee, C., Sellahewa, L., & Pappachan, J. M. (2015) · The Open Respiratory Medicine Journal · doi:10.2174/1874306401408010085 · Cited by 59
Ballı, U., Aydoğdu, A., Dede, F. Ö., Türer, Ç. C., & Güven, B. (2015) · Journal of Periodontology · doi:10.1902/jop.2015.150270 · Cited by 59
Boyce, R. W., Niu, Q., & Ominsky, M. S. (2017) · Bone · doi:10.1016/j.bone.2017.04.005 · Cited by 54
Basha, G., Ordobadi, M., Scott, W. R., Cottle, A., Liu, Y., Wang, H., & Cullis, P. R. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.68 · Cited by 52
Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone
Axelsson, K. F., Nilsson, A. G., Wedel, H., Lundh, D., & Lorentzon, M. (2017) · JAMA · doi:10.1001/jama.2017.8040 · Cited by 53
Monoclonal antibodies for treating osteoporosis
Faienza, M. F., Chiarito, M., D’Amato, G., Colaianni, G., Colucci, S. C., Grano, M., & Brunetti, G. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1401607 · Cited by 55
Updates in CKD-Associated Osteoporosis
Khairallah, P., & Nickolas, T. L. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0491-3 · Cited by 53
Rethinking Bone Disease in Kidney Disease
Damasiewicz, M. J., & Nickolas, T. L. (2018) · JBMR Plus · doi:10.1002/jbm4.10117 · Cited by 65
Zhang, Z. H., Jia, X., Fang, J. Y., Chai, H., Huang, Q., She, C., Jia, P., Geng, D. C., & Xu, W. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15084 · Cited by 56
Nanes, M. S., & Kallen, C. B. (2014) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.06.006 · Cited by 64
The osteoblastic niche in the context of multiple myeloma
Toscani, D., Bolzoni, M., Accardi, F., Aversa, F., & Giuliani, N. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12578 · Cited by 52
Recent developments in osteogenesis imperfecta
Shaker, J. L., Albert, C., Fritz, J. M., & Harris, G. F. (2015) · F1000Research · doi:10.12688/f1000research.6398.1 · Cited by 63
Romosozumab: A Review in Postmenopausal Osteoporosis
Paik, J., & Scott, L. J. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00793-8 · Cited by 56
Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview
Tanaka, Y. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061241 · Cited by 59
Biochemical Markers of Bone Turnover in Osteoporosis
Szulc, P., Bauer, D. C., & Eastell, R. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch35 · Cited by 61
Tominaga, A., Wada, K., Okazaki, K., Nishi, H., Terayama, Y., & Kato, Y. (2021) · Osteoporosis International · doi:10.1007/s00198-021-05925-3 · Cited by 57
Brent, M. B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108383 · Cited by 54
Monoclonal antibodies — A new era in the treatment of multiple myeloma
Jelínek, T., & Hájek, R. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.08.004 · Cited by 52
Osteoblast as a target of anti-osteoporotic treatment
Corrado, A., Sanpaolo, E. R., Bello, S. D., & Cantatore, F. P. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1362312 · Cited by 51
Metadata
- Authors
- McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., Katz, L., Maddox, J., Yang, Y.-C., Libanati, C., & Bone, H. G.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Amgen (United States) (US)
- KU Leuven (BE)
- National Institutes of Health (US)
- Centre hospitalier universitaire de Québec (CA)
- Aarhus University Hospital (DK)
- University of Liège (BE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-30
- Volume
- 370
- Issue
- 5
- Pages
- 412-420
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096627331
- Cited by
- 1,258
- References
- 16
- Citations by year
- 2026: 75 · 2025: 97 · 2024: 82 · 2023: 52 · 2022: 99 · 2021: 93 · 2020: 121 · 2019: 69 · 2018: 90 · 2017: 105 · 2016: 125 · 2015: 139 · 2014: 101
- FWCI
- 160.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- romosozumab, sclerostin, postmenopausal osteoporosis, osteopenia, bone mineral density, bone formation, bone resorption, alendronate, teriparatide, osteocytes, osteoblast activity, monoclonal antibodies, dose comparison, injection site reactions
- MeSH terms
- Aged, Aged, 80 and over, Antibodies, Monoclonal, Calcium, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Lumbar Vertebrae, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Least-Squares Analysis, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.